Table 1.
Key model inputs.
| Parameter | Base case | Range | Distribution | Source | |
|---|---|---|---|---|---|
| Minimum | Maximum | ||||
| Clinical input | |||||
| Survival model for Pola-R-CHP | |||||
| Log-Losgistic model for PFS |
shape = 0.941184 scale = 85.747835 |
Fixed | / | ||
| Log-Losgistic model for OS |
shape = 0.768871 scale = 434.507774 |
Fixed | / | ||
| Survival model for R-CHOP | |||||
| Log-Losgistic model for PFS |
shape = 1.01488 scale = 58.97100 |
Fixed | / | ||
| Exponential model for OS | rate = 0.00411271 | Fixed | / | ||
| Costs input ($) | |||||
| Polatuzumab(30 mg) | 1475.87 | 1180.69 | 1771.04 | Gamma | 16 |
| Rituximab(100 mg) | 198.22 | 158.58 | 237.86 | Gamma | 16 |
| Rituximab(500 mg) | 679.57 | 543.66 | 815.48 | Gamma | 16 |
| Cyclophosphamide(200 mg) | 3.40 | 2.72 | 4.08 | Gamma | 16 |
| Doxorubicin(10 mg) | 3.17 | 2.54 | 3.80 | Gamma | 16 |
| Vincristine(1 mg) | 27.67 | 22.14 | 33.21 | Gamma | 16 |
| Prednisone(5 mg*100) | 0.52 | 0.41 | 0.62 | Gamma | 16 |
| Cost of Brain MRI | 107.85 | 86.28 | 129.42 | Gamma | local hospital |
| Cost of Echocardiogram | 43.99 | 35.19 | 52.79 | Gamma | local hospital |
| Cost of Echocardiography | 4.40 | 3.52 | 5.28 | Gamma | local hospital |
| Cost of Enhanced whole body computed tomography | 335.62 | 268.49 | 402.74 | Gamma | local hospital |
| Cost of Hepatitis B testing | 19.87 | 15.89 | 23.84 | Gamma | local hospital |
| Cost of Laboratory tests per cycle | 27.52 | 22.01 | 33.02 | Gamma | local hospital |
| Cost of Pathologic diagnosis | 822.23 | 657.78 | 986.67 | Gamma | local hospital |
| Cost of PET CT | 1149.47 | 919.58 | 1379.37 | Gamma | local hospital |
| Cost of Primary prophylaxis against neutropenia | 457.52 | 366.02 | 549.02 | Gamma | local hospital |
| Cost of Anemia | 38.60 | 30.88 | 46.32 | Gamma | 18 |
| Cost of Febrile neutropenia | 196.69 | 157.35 | 236.03 | Gamma | 18 |
| Cost of Leukopenia | 222.23 | 177.79 | 266.68 | Gamma | 18 |
| Cost of Neutropenia | 196.69 | 157.35 | 236.03 | Gamma | 18 |
| Cost of Platelet count decreased | 313.34 | 250.67 | 376.01 | Gamma | 18 |
| Cost of Pneumonia | 209.89 | 167.91 | 251.86 | Gamma | 18 |
| Cost of CART | 170292.48 | 136233.98 | 204350.97 | Gamma | 16 |
| Cost of Stem cell transplantation | 38145.51 | 30516.41 | 45774.62 | Gamma | local hospital |
| Cost of Systemic therapy | 3122.03 | 2497.62 | 3746.43 | Gamma | local hospital |
| Cost of Terminal care costs | 18111.31 | 14489.05 | 21733.58 | Gamma | 17 |
| Utility value | |||||
| Utility_in_PD | 0.74 | 0.59 | 0.89 | Beta | 20 |
| Utility_in_PFS | 0.82 | 0.66 | 0.98 | Beta | 20 |
| Disutility of Anemia | −0.09 | −0.07 | −0.11 | Beta | 21 |
| Disutility of Febrile neutropenia | −0.09 | −0.07 | −0.11 | Beta | 22 |
| Disutility of Leukopenia | −0.09 | −0.07 | −0.11 | Beta | 22 |
| Disutility of Neutropenia | −0.16 | −0.13 | −0.19 | Beta | 21 |
| Disutility of Platelet count decreased | −0.11 | −0.09 | −0.13 | Beta | 21 |
| Disutility of Pneumonia | −0.20 | −0.16 | −0.24 | Beta | 23 |
| Others | |||||
| Body surface area (m2) | 1.72 | 1.38 | 2.06 | Gamma | 15 |
| Patient weight | 65 | 52 | 78 | Gamma | 15 |
| Discount rate (%) | 5% | 0% | 8% | Fixed | 15 |
Abbreviations: Pola-R-CHP, polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; OS, overall survival; PD, progressed disease; PFS, progression-free survival; MRI, magnetic resonance imaging; PET CT, positron emission tomography computed tomography; CART, chimeric antigen receptor T-cell immunotherapy.